Haloperidol (DrugBank: Haloperidol)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 8 | ハンチントン病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04071639 (ClinicalTrials.gov) | October 20, 2019 | 26/8/2019 | Symptomatic Therapy for Patients With Huntington's Disease | Randomized Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients | Huntington Disease | Drug: Haloperidol;Drug: Risperidone;Drug: Zoloft;Drug: Coenzyme Q10 | Second Affiliated Hospital, School of Medicine, Zhejiang University | NULL | Recruiting | N/A | N/A | All | 100 | Phase 1 | China |